Strata Skin Sciences ( (SSKN) ) has released its Q2 earnings. Here is a breakdown of the information Strata Skin Sciences presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
STRATA Skin Sciences, Inc. is a medical technology company specializing in the development and marketing of innovative products for treating dermatologic conditions, including psoriasis and vitiligo, using technologies like the XTRAC excimer laser.
In its second quarter of 2025 financial report, STRATA Skin Sciences highlighted significant developments, including the expansion of CPT codes for reimbursement, which could potentially triple the covered patient population in the U.S. The company also reported progress in its lawsuit against LaserOptek and noted strategic device placements.
Key financial metrics for the second quarter of 2025 included a revenue of $7.7 million, marking a 9% decrease compared to the previous year. The company faced a net loss of $2.5 million, with operating expenses rising to $6.5 million from $5.5 million in the prior year. Despite these challenges, STRATA ended the quarter with $6.0 million in cash.
STRATA’s strategic initiatives, such as applying for G-codes and submitting economic data for reimbursement rate increases, aim to enhance future growth. The company is also focusing on expanding its patient pool through direct-to-consumer efforts and strengthening partnerships with practice partners.
Looking ahead, STRATA’s management remains optimistic about the potential positive impact of the expanded reimbursement codes and strategic growth initiatives, despite the seasonal fluctuations in business performance. The company is committed to managing costs and expanding its market presence.